“Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 1 Trial”, J of Skin, vol. 8, no. 6, p. s445, Nov. 2024, doi: 10.25251/skin.8.supp.445.